GDC-0349, with the CAS number 1207360-89-1, is a small molecule inhibitor primarily targeting the Hedgehog signaling pathway, which plays a crucial role in cell growth and differentiation. This compound has been investigated for its potential therapeutic applications in treating various cancers, particularly those associated with aberrant Hedgehog signaling, such as basal cell carcinoma and medulloblastoma. GDC-0349 exhibits selective inhibition of Smoothened (SMO), a key component of the Hedgehog pathway, thereby disrupting the signaling cascade that promotes tumor growth. The substance is characterized by its moderate solubility in organic solvents and relatively low solubility in water, which can influence its bioavailability and pharmacokinetics. In preclinical studies, GDC-0349 has shown promising antitumor activity, leading to its evaluation in clinical trials. As with many investigational drugs, its safety profile, efficacy, and optimal dosing regimens are subjects of ongoing research.

GDC-0349

1207360-89-1: GDC-0349, with the CAS number 1207360-89-1, is a small molecule inhibitor primarily targeting the Hedgehog signaling pathway, which plays a crucial role in cell growth and differentiation. This compound has been investigated for its potential therapeutic applications in treating various cancers, particularly those associated with aberrant Hedgehog signaling, such as basal cell carcinoma and medulloblastoma. GDC-0349 exhibits selective inhibition of Smoothened (SMO), a key component of the Hedgehog pathway, thereby disrupting the signaling cascade that promotes tumor growth. The substance is characterized by its moderate solubility in organic solvents and relatively low solubility in water, which can influence its bioavailability and pharmacokinetics. In preclinical studies, GDC-0349 has shown promising antitumor activity, leading to its evaluation in clinical trials. As with many investigational drugs, its safety profile, efficacy, and optimal dosing regimens are subjects of ongoing research.

(S)-1-Ethyl-3-(4-(4-(3-methylmorpholino)-7-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)urea

<p>GDC-0349 (RG-7603) is a potent and selective ATP-competitive inhibitor of mTOR, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1.</p>

CAS 1207360-89-1

GDC-0349

(S)-1-Ethyl-3-(4-(4-(3-methylmorpholino)-7-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)urea

Ref: IN-DA008TGC

GDC-0349

Ref: 54-BUP13147

GDC-0349

Ref: TM-T6510